Response assessment of complete response (CR), partial response (PR), long stable disease (SD) for >3 months with a cancer immunotherapy treatment for metastatic cancer or hematologic malignancies either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
Availability of tumor biopsy material extracted and preserved by the investigating site.

NCT03333655_inc_T1
Measurement
Response assessment
NCT03333655_inc_T2
Value
complete response (CR)
NCT03333655_inc_T3
Value
partial response (PR)
NCT03333655_inc_T4
Value
long stable disease (SD)
NCT03333655_inc_T5
Temporal
for >3 months
NCT03333655_inc_T6
Scope
complete response (CR), partial response (PR), long stable disease (SD)
NCT03333655_inc_T7
Qualifier
cancer
NCT03333655_inc_T8
Procedure
immunotherapy treatment
NCT03333655_inc_T9
Condition
metastatic cancer
NCT03333655_inc_T10
Condition
hematologic malignancies
NCT03333655_inc_T11
Procedure
marketed CPI
NCT03333655_inc_T12
Observation
participation in a Roche/Genentech CPI clinical trial
NCT03333655_inc_T13
Scope
metastatic cancer or hematologic malignancies